Zydus gets DCGI nod for drug to treat anaemia associated with chronic kidney disease
Zydus Lifesciences on Monday said it has received an approval from the Drug Controller General of India (DCGI) for Oxemia (Desidustat), a first-of-its-kind oral treatment for anaemia associated with chronic kidney disease (CKD). The drug firm, formerly known as Cadila Healthcare, said it has received approval for its new drug application (NDA) the product. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 7, 2022 Category: Pharmaceuticals Source Type: news
EU OKs Difelikefalin for CKD-Associated Pruritus, Generic Diabetes Meds EU OKs Difelikefalin for CKD-Associated Pruritus, Generic Diabetes Meds
CHMP adopts positive opinions for a new drug for pruritis associated with chronic kidney disease, two biosimilar insulins, and a generic form of the DPP-4 inhibitor sitagliptin for type 2 diabetes.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 1, 2022 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Source Type: news
Lupin launches generic medication in US market
Lupin has launched Sevelamer Hydrochloride tablets (800 mg), used to treat hyperphosphatemia in patients with chronic kidney disease, in the US market. The company has launched the product after having received approval from the US Food and Drug Administration (USFDA). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2022 Category: Pharmaceuticals Source Type: news
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
PLANO, Texas--(BUSINESS WIRE) February 25, 2022 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the“Company,” or“we”), today announced that the U.S. Food and Drug Administration (“FDA”) has... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 25, 2022 Category: Drugs & Pharmacology Source Type: news
New Models Improve ASCVD Risk Prediction in Chronic Kidney Disease
TUESDAY, Feb. 15, 2022 -- For patients with chronic kidney disease (CKD), 10-year atherosclerotic cardiovascular disease (ASCVD) risk prediction models, including clinical variables and biomarkers, improve risk prediction compared with traditional... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 15, 2022 Category: Pharmaceuticals Source Type: news
Biomarkers Predict Cardiovascular Risk in Chronic Kidney Disease Patients Biomarkers Predict Cardiovascular Risk in Chronic Kidney Disease Patients
Models using novel biomarkers were the most effective predictors of 10-year risk for atherosclerotic cardiovascular disease in patients with chronic kidney disease, a new study found.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 12, 2022 Category: Cardiology Tags: Nephrology News Source Type: news
SGLT2 Inhibitors and HF Outcomes Across Patient Populations SGLT2 Inhibitors and HF Outcomes Across Patient Populations
This brief paper summarizes recent trials on the efficacy of SGLT2 inhibitors in heart failure patients with diabetes, chronic kidney disease, HFrEF, HFpEF, and worsening HF.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 9, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Antimineralocorticoids May Protect Against Kidney Failure in CKD Antimineralocorticoids May Protect Against Kidney Failure in CKD
For patients with chronic kidney disease, treatment with a mineralocorticoid-receptor antagonist appears to protect against kidney failure requiring renal replacement therapy, according to a retrospective cohort study.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 4, 2022 Category: Intensive Care Tags: Nephrology News Source Type: news
Obesity Rate Increasing in U.S. Adults With Type 1 Diabetes
MONDAY, Jan. 31, 2022 -- The prevalence of obesity is increasing among individuals with type 1 diabetes (T1D), and it is associated with an elevated risk for chronic kidney disease, according to a study published online Jan. 26 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2022 Category: Pharmaceuticals Source Type: news
"Sarcopenia and risk of osteoporosis, falls and bone fractures in patients with chronic kidney disease: a systematic review" - Rashid A, Chaudhary Hauge S, Suetta C, Hansen D.
BACKGROUND: Chronic kidney disease [CKD] has been suggested to increase the risk of osteoporosis, sarcopenia, falls, and fractures. The aim of this systematic review was to explore the occurrence of osteoporosis, falls, and fractures in patients with sarco... (Source: SafetyLit)
Source: SafetyLit - January 27, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
JBCPL to buy probiotic and reproductive brands from Sanzyme for Rs 628 crore
The acquired portfolio includes Sporlac which is the third largest probiotics brand in India and specialized products such as Lobun - a probiotic used for delaying progression of Chronic Kidney Disease and Oxalo - an alternate risk-free therapy to decalcify kidney stones. The reproductive health segment has a complete range of infertility and hormone products. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 26, 2022 Category: Pharmaceuticals Source Type: news
Allopurinol Not Tied to Higher Mortality for Patients With Gout and CKD
TUESDAY, Jan. 25, 2022 -- For patients with gout and chronic kidney disease (CKD), no associations with increased mortality were seen for allopurinol initiation, achieving target serum urate (SU) levels, or allopurinol dose escalation, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 25, 2022 Category: Pharmaceuticals Source Type: news
Allopurinol Found Safe in Patients With Concomitant Gout, CKD Allopurinol Found Safe in Patients With Concomitant Gout, CKD
Despite earlier concerns, a study has found no sign of increased mortality with allopurinol therapy in patients with gout and chronic kidney disease.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - January 25, 2022 Category: Rheumatology Tags: Rheumatology News Source Type: news
eGFR Slope Tracks Kidney Disease in Cardiovascular Trials eGFR Slope Tracks Kidney Disease in Cardiovascular Trials
A new review proposes using the slope of estimated glomerular filtration rate (eGFR) as a surrogate measure of chronic kidney disease progression in cardiovascular outcome trials.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - January 6, 2022 Category: Transplant Surgery Tags: Nephrology News Source Type: news
Dapagliflozin in Patients With CKD, With and Without HF Dapagliflozin in Patients With CKD, With and Without HF
Heart failure is common in patients with chronic kidney disease. Might the SGLT-2 inhibitor dapagliflozin reduce the risk of kidney failure and cardiovascular death in these patients?JACC: Heart Failure (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - January 3, 2022 Category: Intensive Care Tags: Cardiology Journal Article Source Type: news
